BioSpace News Archive

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks.

Coya Therapeutics, Inc. today announced the appointment of Arun Swaminathan, Ph.D. to the role of Chief Business Officer.

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today that the Company will host an Investor Day on Tuesday, April 4, 2023, starting at 8:00 am ET.

Covalon Technologies Ltd. today announced the second expert-led webinar in its CLABSI Conscious campaign, titled “Protecting CVADs from Gross Contamination”, to be held on Wednesday, March 29 at 1pm EDT.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, announced that members of its management team will participate in the following investor conferences,.

Daxor Corporation, the global leader in blood volume measurement technology, announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023.

Terns Pharmaceuticals, Inc. today announced the appointment of Emil Kuriakose, M.D. as chief medical officer of Terns oncology, effective May 1, 2023.

On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging (IMI) agents to target and illuminate cancer during surgery, today announced publication of results from the ELUCIDATE Phase 3 Trial of CYTALUX (pafolacianine) injection for use of IMI for cancer in the lung.

Aadi Bioscience, Inc. today announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors.

Vertex Pharmaceuticals Incorporated today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).